US Patent

US11590205 — Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Method of Use · Assigned to Xeris Pharmaceuticals Inc · Expires 2036-04-22 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for making stable formulations of a therapeutic glucagon agent using a specific type of solvent and excipient.

USPTO Abstract

Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

Drugs covered by this patent

Glucagen (GLUCAGON) · Xeris

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2742`	—	Glucagen
`U-2742`	—	Glucagen
`U-2742`	—	Glucagen
`U-2742`	—	Glucagen
`U-2742`	—	Glucagen

Patent Metadata

Patent number: US11590205
Jurisdiction: US
Classification: Method of Use
Expires: 2036-04-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Xeris Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.